Leaflet DEPAKINE 57.64mg / ml syrup
Indicated for: epilepsy; bipolar disorder
Route of administration: oral
Substance: valproic acid + salts (antiepileptics)
ATC: N03AG01 (Nervous system | Antiepileptics | Fatty acid derivatives)
This medicine may affect your ability to drive or use machines.
Dose adjustment may be needed in liver disease.
Dose adjustment may be needed in kidney disease.
This medicine may cause dizziness or vertigo.
Effective contraception is required during treatment.
Do not use this medicine during pregnancy.
Periodic laboratory tests may be required during treatment.
Seek medical help if suicidal thoughts or major behavior changes occur.
This medicine may affect fetal development.
This medicine may cause drowsiness or reduced alertness.
Valproic acid and its salts, such as sodium valproate or semisodium valproate, are medicines used for epilepsy and bipolar disorder; in some countries they have also been used for migraine prevention. Valproate stabilises electrical activity in the brain and influences certain neurotransmitters. It can be effective but has important risks.
It is taken by mouth or, in hospital, given intravenously according to the doctor’s instructions. The dose is adjusted individually and blood levels may sometimes be monitored. Do not stop treatment suddenly, because seizures or relapse may occur. It is important to take the medicine regularly and tell the doctor about all other treatments.
Side effects may include nausea, tremor, sleepiness, weight gain, hair loss, menstrual changes, liver test abnormalities, low platelets or pancreatitis. Mood changes, confusion or increased ammonia may occur. Blood tests for liver function, blood counts and sometimes medicine levels may be needed during treatment.
Valproate can cause birth defects and developmental disorders in children exposed during pregnancy. Women and girls who can become pregnant must discuss contraception and alternatives with their doctor. Seek urgent help for severe abdominal pain, persistent vomiting, jaundice, bleeding, extreme sleepiness, worsening seizures or thoughts of self-harm.
General data about DEPAKINE 57.64mg / ml
- Substance: valproic acid + salts
- Date of latest medicines list: 01-06-2026
- Product code: W64489002
- Concentration: 57.64mg / ml
- Pharmaceutical form: syrup
- Packing volume: 150 ml
- Product type: Original
- Price: 23.35 RON
- Prescription status: P-6L - Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.
Pharmaceutical forms available for valproic acid + salts
- capsules with prolonged-release mini-tablets
- prolonged release capsules
- gastro-resistant soft capsules
- prolonged-release tablets
- film-coated tablets
- modified-release film-coated tablets
- gastro-resistant film-coated tablets
- gastro-resistant tablets
- prolonged-release granules
- lyophilisate and solvent for solution
- syrup
Concentrations available for valproic acid + salts
- 1000mg
- 100mg
- 150mg
- 200mg
- 200mg/5ml
- 250mg
- 300mg
- 300mg/5ml
- 400mg/4ml
- 500mg
- 50mg/ml
- 57.64mg/ml
- 600mg
- 750mg
Compensation lists for DEPAKINE 57.64mg / ml Sanofi
GX (C1) - GENERIC (used in compensation list, C1, for another diagnosis)
Price
Copayment
Patient
23.35 RON
23.35 RON
0.00 RON